Specialty Pharmacy

The decentralization of US health care, accelerated by virtual care adoption, shifting reimbursement models, and a growing demand for complex therapies, is elevating the role of specialty and infusion pharmacies as essential, tech-enabled partners in delivering coordinated, patient-centered care across outpatient and home-based settings.

High levels of remnant cholesterol were associated with increased risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD) independent of low-density lipoprotein cholesterol (LDL-C).

The approval represents a major advancement for patients with moderate-to-severe chronic hand eczema, as delgocitinib becomes the first treatment available for this population in the US.

A human-first support model helped boost adherence and outcomes, proving emotional connection is key to specialty medication success.

In the double-blind portion of Vibrance-1, alixorexton improved wakefulness while eliciting broad benefits in patient-reported outcomes.

Challenges faced by individuals living with HIV include weight gain, cardiovascular risks, and healthy aging strategies.

New research shows effective interventions can reduce prescriptions across all ages.

Experts discussed the promising future of pericarditis treatment.

The new formulation contains little IgA, reducing possible risks associated with infusion in patients with primary immunodeficiency.

Prescription digital therapeutics (PDTs) offer scalable, accessible alternatives to traditional treatments—supporting patients, providers, and payers while addressing gaps in mental health care.

Real-world data show that patients switching from Humira to biosimilars Hadlima and Hyrimoz achieve similar outcomes without hospitalization.

Expert explores the expanding role of FDA-approved Prescription Digital Therapeutics (PDTs).

The letter cited deficiencies previously identified at a third-party manufacturing vendor unrelated to oxylanthanum carbonate (OLC).

The injection is indicated for the treatment of sepsis and other serious infections, enhancing treatment efficiency and patient care.

Pharmacists and clinicians collaborate to carefully manage rilonacept therapy.

The FDA approves emapalumab-lzsg as the first treatment for macrophage activation syndrome in Still disease, offering a new treatment approach for patients with the rare condition.

Intravenous immunoglobulin (IVIG) use over an extended period in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) was potentially associated with a reduced incidence of cancer over time, although more research is necessary.

Explore the latest FDA-approved novel drugs transforming treatment options for various conditions, enhancing patient care and outcomes in community and specialty pharmacy.

In March, Utah became the first state to completely ban fluoridation.

Glucocorticoids alone were found to reduce treatment failure and fever duration, but the combination with intravenous immunoglobulin (IVIG) significantly reduced the need for adjunctive immunotherapy following treatment.

The FDA approves dupilumab as the first targeted treatment for bullous pemphigoid, offering hope for patients with this debilitating skin condition.

Amy Duong, PharmD, BCACP, highlights the importance of patient counseling and addressing logistical challenges in treating patients with chronic inflammatory demyelinating neuropathy (CIDP).

Its approval was based on data from a 3-year trial that enrolled patients with alkaptonuria.

In the first half of 2025, the FDA approved 7 novel drugs for oncologic conditions, including for non-small cell lung cancer; ovarian cancer; and metastatic, hormone receptor-positive, human epidermal growth factor 2-negative breast cancer.

The authors note that the combinatorial principal component analysis (cPCA) may be effective in other complex diseases outside of chronic kidney disease (CKD).

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Explore the evolving role of pharmacists in patient care, emphasizing personalized services, community health, and innovative solutions for better health outcomes.

Amy Duong, PharmD, BCACP, explains pharmacists' critical role in promoting chronic inflammatory demyelinating neuropathy (CIDP) treatment adherence and staying informed about new therapeutic developments.